Enhancing protective immunity against RSV by inhibitors of sphingolipid synthesis

通过鞘脂合成抑制剂增强对 RSV 的保护性免疫力

基本信息

  • 批准号:
    10354486
  • 负责人:
  • 金额:
    $ 26.94万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-05-09 至 2024-04-30
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY Infections with respiratory syncytial virus (RSV) are a considerable global health threat with high morbidity and mortality in populations at risk, especially young children. Despite decades of intense efforts, a safe and effective vaccine against RSV is not available. The development of an active immunization strategy has been hampered by the risk for severe lung disease. Severe RSV lung disease first occurred in small children who had been vaccinated with a formalin- inactivated vaccine upon infection with RSV. Lessons learned from studying severe RSV disease, and responses to RSV antigens point to the need for a successful vaccine to induce robust Th1-biased immune response and potent neutralizing antibodies. We found that simultaneous inhibition of sphingolipid de novo synthesis and mucosal administration RSV induces a robust, Th1 biased and protective immune responses. We hypothesize that inhibitors of serine-palmitoyl CoA transferase (SPT), the rate-limiting step of sphingolipid synthesis, can function as potent adjuvants to enhance and favorably shape the immunogenicity of an RSV vaccine. Further, the mechanism of this novel adjuvant strategy might differ substantially from the pro-inflammatory and TLR-activating properties of other adjuvants. The aims of this exploratory proposal are two-fold: First, to confirm the adjuvant effect of SPT-inhibitors for a variety or biological relevant variables and targets for a RSV vaccine, most importantly the capacity to enhance Th1 immunity and to lower the risk for vaccine-enhanced disease. Second, to elucidate the innate immune mechanisms that trigger the increased adaptive immune responses. Given the early stage of this project, we will focus mostly on lung dendritic cells and potential alterations in immune cell trafficking induced by changes in pulmonary mucosal sphingolipid synthesis. These results could then inform further detailed immune characterization of other potentially affected cells, such as T follicular helper and regulatory cells and further development of SPT-inhibitors as potential adjuvants for vaccines against other respiratory pathogens.
项目总结 呼吸道合胞病毒(RSV)感染是一个相当大的全球健康威胁,具有很高的 高危人群,特别是幼儿的发病率和死亡率。尽管几十年来 尽管进行了激烈的努力,但目前还没有安全有效的RSV疫苗。的发展。 由于存在严重肺部疾病的风险,积极的免疫战略受到了阻碍。严重者 呼吸道合胞病毒肺病最早发生在接种了福尔马林疫苗的小孩子身上。 感染RSV后的灭活疫苗。研究严重呼吸道合胞病毒的经验教训 疾病和对RSV抗原的反应表明,需要一种成功的疫苗来诱导 强大的Th1偏向免疫反应和强大的中和抗体。我们发现 RSV同时抑制鞘磷脂从头合成和粘膜给药 诱导强大的、偏向Th1的和保护性的免疫反应。我们假设抑制物 丝氨酸棕榈酰辅酶A转移酶(SPT)是鞘磷脂合成的限速步骤,可以 作为有效的佐剂来增强和有利地塑造RSV的免疫原性 疫苗。此外,这种新的佐剂策略的机制可能与 其他佐剂的促炎和激活TLR的特性。这样做的目的是 探索性建议有两个方面:第一,确认SPT-抑制剂对 RSV疫苗的品种或生物相关变量和靶点,最重要的是 增强Th1免疫和降低疫苗增强型疾病风险的能力。第二, 阐明触发获得性免疫增强的先天免疫机制 回应。鉴于这个项目的早期阶段,我们将主要关注肺树突状细胞和 肺粘膜改变可能引起的免疫细胞转运的改变 鞘脂合成。这些结果可以为更详细的免疫特性提供信息 其他可能受影响的细胞,如T滤泡辅助细胞和调节细胞,以及进一步 SPT抑制剂作为其他呼吸道疫苗潜在佐剂的研究进展 病原体。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Stefan Worgall其他文献

Stefan Worgall的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Stefan Worgall', 18)}}的其他基金

Impact of SARS-CoV-2 infection on respiratory viral immune responses in children with and without asthma
SARS-CoV-2 感染对患有和不患有哮喘的儿童呼吸道病毒免疫反应的影响
  • 批准号:
    10568344
  • 财政年份:
    2023
  • 资助金额:
    $ 26.94万
  • 项目类别:
Respiratory sphingolipid synthesis involved in airway hyperreactivity and viral-triggered asthma
呼吸鞘脂合成参与气道高反应性和病毒引发的哮喘
  • 批准号:
    10660726
  • 财政年份:
    2023
  • 资助金额:
    $ 26.94万
  • 项目类别:
Enhancing protective immunity against RSV by inhibitors of sphingolipid synthesis
通过鞘脂合成抑制剂增强对 RSV 的保护性免疫力
  • 批准号:
    10619550
  • 财政年份:
    2022
  • 资助金额:
    $ 26.94万
  • 项目类别:
Mucosal Immunization Against P. aeruginosa by Modified Adenovirus Vectors
改良腺病毒载体针对铜绿假单胞菌的粘膜免疫
  • 批准号:
    8662189
  • 财政年份:
    2013
  • 资助金额:
    $ 26.94万
  • 项目类别:
Mucosal Immunization Against P. aeruginosa by Modified Adenovirus Vectors
改良腺病毒载体针对铜绿假单胞菌的粘膜免疫
  • 批准号:
    9040866
  • 财政年份:
    2013
  • 资助金额:
    $ 26.94万
  • 项目类别:
Mucosal Immunization Against P. aeruginosa by Modified Adenovirus Vectors
改良腺病毒载体针对铜绿假单胞菌的粘膜免疫
  • 批准号:
    8579420
  • 财政年份:
    2013
  • 资助金额:
    $ 26.94万
  • 项目类别:
Vaccination Against RSV with Capsid-modified Ad Vectors
使用衣壳修饰的广告载体进行 RSV 疫苗接种
  • 批准号:
    7654470
  • 财政年份:
    2009
  • 资助金额:
    $ 26.94万
  • 项目类别:
Vaccination Against RSV with Capsid-modified Ad Vectors
使用衣壳修饰的广告载体进行 RSV 疫苗接种
  • 批准号:
    7847618
  • 财政年份:
    2009
  • 资助金额:
    $ 26.94万
  • 项目类别:
Immunity Induced by Modified Adenovirus Fiber
修饰腺病毒纤维诱导免疫
  • 批准号:
    7625061
  • 财政年份:
    2007
  • 资助金额:
    $ 26.94万
  • 项目类别:
Immunity Induced by Modified Adenovirus Fiber
修饰腺病毒纤维诱导免疫
  • 批准号:
    7315733
  • 财政年份:
    2007
  • 资助金额:
    $ 26.94万
  • 项目类别:

相似海外基金

Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
  • 批准号:
    23K08213
  • 财政年份:
    2023
  • 资助金额:
    $ 26.94万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
  • 批准号:
    2881726
  • 财政年份:
    2023
  • 资助金额:
    $ 26.94万
  • 项目类别:
    Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 26.94万
  • 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
  • 批准号:
    10722146
  • 财政年份:
    2023
  • 资助金额:
    $ 26.94万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 26.94万
  • 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
  • 批准号:
    10935776
  • 财政年份:
    2023
  • 资助金额:
    $ 26.94万
  • 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
  • 批准号:
    10935796
  • 财政年份:
    2023
  • 资助金额:
    $ 26.94万
  • 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
  • 批准号:
    10935775
  • 财政年份:
    2023
  • 资助金额:
    $ 26.94万
  • 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
  • 批准号:
    10735964
  • 财政年份:
    2023
  • 资助金额:
    $ 26.94万
  • 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
  • 批准号:
    10649041
  • 财政年份:
    2023
  • 资助金额:
    $ 26.94万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了